Arcutis Biotherapeutics, Inc. - Common stock (ARQT)

Competitors to Arcutis Biotherapeutics, Inc. - Common stock (ARQT)

Amgen Inc. 

Amgen is a biotechnology company that develops therapies for various skin conditions, including psoriasis and atopic dermatitis, similar to Arcutis. With its established portfolio of drugs and significant resources, Amgen has a competitive edge in market penetration and research capabilities. This means they can invest heavily in clinical trials and market strategies, giving them an advantage in the dermatological market.

Cymabay Therapeutics, Inc.

Cymabay Therapeutics explores therapies for chronic liver disease and hyperlipidemia, positioning itself differently from Arcutis. However, it indirectly competes for investment and attention in the biotech space. While Cymabay has a narrower focus, this may limit their competition directly against Arcutis's specific dermatology roster, putting them at a disadvantage in targeting the same customer segments.

Eli Lilly and Company 

Eli Lilly has a strong presence in immunology and dermatology, with a portfolio that includes treatments for psoriasis and other skin ailments. Their established brand recognition and extensive clinical development experience provide them with an advantage in bringing new therapies to market swiftly. Additionally, their scale and distribution networks offer them a substantial lead in terms of market reach compared to Arcutis.

Incyte Corporation 

Incyte competes by developing treatments for dermatological diseases, particularly those linked to immune responses. They have a competitive edge in their focus on targeted therapies and their experience in the oncology and immunology markets, suggesting they have a robust research and development pipeline. While Incyte is experienced, its resources are not as extensive as larger competitors, putting them slightly behind in overall market influence.

Regeneron Pharmaceuticals, Inc. 

Regeneron competes in the same therapeutic areas with products like Dupixent, which is used for atopic dermatitis and other allergic conditions. The company has a competitive advantage through its proprietary technologies and established market presence, enabling it to uphold a strong position in the biologics market. Their innovations and focus on monoclonal antibodies allow them to capture significant market share over emerging competitors like Arcutis.